An interventional study of Epigenome-Guided Treatment Arm and Investigator-Guided Treatment Arm in Crohn Disease (CD), sponsored by Alimentiv Inc.. Recruiting at 51 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Alimentiv Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies in Crohn Disease with a site in Belgium — 41 open to participants now, 56 under way, 29 of them phase 3. Crohn Disease · Belgium.
Among the 194 studies in Crohn Disease with a site in Belgium, this one is the 60th largest by planned enrollment of the 175 interventional ones that give a count, is one of 13 that started in 2025, is one of 12 with no phase, reaches primary completion later than 34 of the 55 other live ones, and was the 189th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →41 of the 194 studies in Crohn Disease with a site in Belgium are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Belgium, United States, Argentina and 27 more countries
Ages 18+
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Imelda GI Clinical Research Center · Sites in Belgium
Ages 16+
Janssen Research & Development, LLC · Sites in Belgium, United States, Austria and 14 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 58 · Phase 3 94 · Phase 4 9
First in 2001; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 378 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 211 across the 175 interventional studies, 257 across the 19 observational. Of the 135 that completed or were terminated, 83 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 194 have an industry lead sponsor. The 10 most frequent:
Alimentiv Inc. is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
Alimentiv Inc. has 7 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Crohn Disease with a site in Belgium that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
Add all 15 to your calendar (.ics) → With an account.
Among the 194 studies in Crohn Disease with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicentre, prospective, randomised, controlled, open-label study to assess the efficacy, safety, and cost-effectiveness of epigenome-guided treatment selection compared to usual standard-of-care (SOC) treatment selection in patients initiating biologic therapy for the treatment of their active Crohn's Disease (CD).
This trial will include 378 participants with active CD, defined as an HBI > 4 and the presence of endoscopic ulceration. Approximately 50% of the enrolled population will be bio-naïve and 50% exposed to no more than 1 prior biologic.
Eligible participants will be randomised 1:1 to either epigenome-guided treatment selection or usual SOC treatment selection. Randomization will be stratified by prior biologic use (yes/no) and corticosteroid use (yes/no) at baseline.
Blood samples for the assessment will be collected for all participants during screening. Peripheral blood will be tested via a machine-learning-powered epigenetic biomarker assay. EpiPredict is a software designed for CSV file input, data transfer, storage, and display, and will be serving as a EpiPredict clinical decision support system. It recommends treatment selections for 2 biologics (Vedolizumab (VDZ) and Vedolizumab (UST)) for CD utilizing genetic data.
The intervention (EpiPredict software) will indicate the probability of response to both VDZ and UST (though sites will only be provided with the treatment with the highest outcome) for the treatment of CD using a hybrid capture-based methylation assay (approved for research use only) and the EpiPredict software.
All participants in the study will be administered their biologic therapy in accordance with the product label and local SOC recommendations. Dose adjustments will be allowed in both groups at the treating investigator's discretion.
During the 26-week treatment period, the study assessments will follow the SOC regimen of the assigned biologic treatment. For participants receiving VDZ, study assessments are to occur at Weeks 6, 14, and 26; for participants receiving UST, study assessments are to occur at Weeks 8, 16, and 26.
Long-term follow up assessments are to occur every 6 months (Months 12, 18, and 24) after Week 26. Data for long-term follow up assessments will be collected from the participant's medical records captured at routine SOC visits and online questionnaires.
The criteria were revised on the registry on Nov 3, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all of the following criteria for enrolment into the study:
If receiving oral , the participant is eligible if they meet all the following criteria:
Exclusion Criteria:
Participants who meet any of the following criteria are to be excluded from the study:
CD-related complications that in the opinion of the investigator would interfere with participation in the study, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Investigator-Guided Treatment Arm
Device: Epigenome-Guided Treatment Arm
Participants will receive UST or VDZ biologic therapy as indicated by an epigenome read-out of peripheral blood using a hybrid capture-based methylation assay. The assay and EpiPredict software will indicate the probability of response to VDZ and UST. The biologic with the predicted highest likelihood of success will be communicated to the investigator and the biologic initiated using standard dosing regimens.
Assigned to UST or VDZ per conventional SOC and without the use or knowledge of epigenome results.
To compare the efficacy of epigenome-guided treatment selection to usual SOC treatment selection for inducing clinical remission and endoscopic response at Week 26 in participants with active CD.
Corticosteroid-free clinical remission (Harvey-Bradshaw Index \[HBI\] score ≤ 4) and endoscopic response (≥ 50% decrease from baseline in the Simple Endoscopic Score for Crohn's Disease \[SES-CD\])
Time frame: Baseline to Week 26
To explore the optimal threshold of EpiPredict results in predicting treatment response using data from participants assigned to the epigenome-guided treatment selection group
Receiver-operating characteristic curve area analysis will be used Predicted likelihood of success of reaching corticosteroid-free clinical remission and endoscopic response
Time frame: Baseline to Week 26
To compare the efficacy of epigenome-guided treatment selection to usual SOC treatment selection for improving clinical and endoscopic outcome measures at Week 26 in participants with active CD
Endoscopic response (≥ 50% decrease from baseline in SES-CD score) Endoscopic remission (SES-CD ≤ 3) Clinical remission (HBI ≤ 4) Corticosteroid-free clinical remission Clinical response (HBI ≤ 4 or decrease in HBI ≥ 3 points from baseline) Corticosteroid-free deep remission (HBI ≤ 4 and SES-CD ≤ 3)
Time frame: Baseline to Week 26
To evaluate the cost-effectiveness of epigenome-guided treatment selection compared to usual SOC treatment selection
Societal costs as measured by the modified iMTA Medical Cost Questionnaire and modified iMTA Productivity Cost Questionnaire questionnaires Quality of life-years as measured by the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) questionnaire
Time frame: Baseline to 24 Months
To assess the safety of a treatment based on epigenome-guided treatment selection compared to usual SOC treatment selection
Adverse events CD-related complications, hospitalisations, and/or surgeries
Time frame: Baseline to Week 26
To explore additional efficacy measures of epigenome-guided treatment selection compared to usual SOC treatment selection at Week 26 in participants with active CD.
Achieving a minimally clinically important difference in patient-reported health-related quality of life (HRQOL) compared to baseline as measured by the EQ-5D-5L Clinical remission (HBI ≤ 4) Clinical response (HBI ≤ 4 or decrease in HBI ≥ 3 points from baseline) Clinical remission (Crohn's Disease Activity Index \[CDAI\] score of \< 150) over time Time to clinical remission (HBI ≤ 4) No drainage on gentle finger compression in participants with draining fistulas Extra-intestinal manifestations Histologic response, as defined in the statistical analysis plan (SAP) Histologic remission, as defined in the SAP Whether the participant achieved 25%, 50%, and 75% reduction from baseline in the Robarts Histopathology Index (RHI) score Serum trough concentrations of biologic drug Biochemical remission CRP ≤ 5.0 mg/L and/or fecal calprotectin \[FC\] \< 250 µg/g) Change in the Symptoms and Impact Questionnaire-CD (SIQ-CD) score
Time frame: Baseline to Week 26
In a subset (~30%) of participants, to evaluate response by intestinal ultrasound (IUS) in participants assigned to epigenome-guided treatment selection compared to usual SOC treatment selection
Proportion of participants with IUS response (defined as by reduction in bowel wall thickness \[BWT \> 25%\] or \[\> 2.0 mm\] or \[\> 1.0 mm and one colour Doppler signal (CDS) reduction\]) Proportion of participants with transmural remission (defined by BWT ≤ 3 mm and normal/0 CDS) Proportion of participants with transmural remission and endoscopic remission
Time frame: Baseline to Week 26
Started Feb 2025 (actual). Primary completion is estimated for Aug 2028, 42 months after the start.
Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 42 months is close to that.
Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Jun 2027 → Aug 2028 and completion Jan 2029 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alimentiv Inc.